The deal only closed in 2015, and so this looks like a ridiculous major U-turn in just three years for a big pharma. Incoherent long-term strategy from where I sit.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.